TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices

October 29, 2020

Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and Community Oncology Cancer Centers in the United States

Translational Drug Development (TD2), a precision oncology contract research organization (CRO), and VieCure have announced a strategic partnership that will provide patients receiving care in community oncology practices with best-in-class precision oncology treatments while enhancing patient awareness of tailored treatment and clinical studies that are most likely to benefit them.

A paradigm shift has occurred in favor of precision oncology, in which the molecular profile of a patient’s tumor is guiding treatment related decision-making. There has been an unprecedented increase in the number of approved novel immunotherapy and targeted agents across different indications over the past five years. The combination of TD2 and VieCure will allow a greater number of oncologists to embrace the latest clinical guidance, increase access to trials, have ease of access to next generation tumor sequencing, and facilitate enhanced access to the right care, for the right patient, at the right time.

“We believe community oncology practices are critical to the success for new oncology medicines and this partnership increases the likelihood of clinical benefit for patients and overall success of clinical trials, “said Stephen Gately, President and CEO at TD2. “VieCure’s platform puts critical patient data like genomics, and proteomics at oncologist’s fingertips as they meet with their patients so that they are immediately aware of potential precision oncology trials that their patient is eligible for.”

Access to de-identified real-time patient data will enhance TD2’s ability to identify the right patients with much greater fidelity and speed, ultimately resulting in better outcomes for cancer patients.

“The VieCure™ Platform is the ideal vehicle to help drive precision oncology adoption in community-based practice,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure, “Our Artificial Intelligence engine supports clinicians by presenting options that may have otherwise gone unnoticed, further emphasizing the need for clinical decision support tools at the point of care to help manage the precision oncology revolution.”

Participating community oncology practices will have access to industry-sponsored clinical trials codified into the VieCure™ platform. This will improve trial design and speed up the opening of precision oncology clinical trials and the real time collection of data in the community oncology setting. This relationship will result in a greater number of patients having access to new and novel therapies.

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.